Skip to main content
. 2022 Feb 8;10(2):401. doi: 10.3390/biomedicines10020401

Figure 6.

Figure 6

Possible molecular mechanisms for development of Atherogenic Dyslipidemia, liver dysfunction and hyperuricemia in insulin resistance. FFA, free fatty acid; GLUT9, glucose transporter 9; HDL, high-density lipoprotein; HSL, hormone sensitive lipase; LPL, lipoprotein lipase; TG, triglyceride; UA, uric acid; URAT1, urate transporter 1; VLDL, very-low density-lipoprotein.